Insmed, Inc.(INSM)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $90.39 – $212.75
- YTD
- -41.31%
- IV Rank (30D)
- 58.91
- Straddle Price
- $11.25
- P/C Vol Ratio
- 0.36
- Market Cap
- $22.6B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.50% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.00% (VRP-adj) |
| WACC | 9.51% |
| Volatility Risk Premium | +30.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.9B |
| Return on Equity (TTM) | -167.9% |
| Book / Price | 3.3% |
| Gross Margin (TTM) | 81.8% |
| FCF Margin (TTM) | -110.2% |
| Debt / Equity | 0.80 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $115.19 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $100.18 |
| Bollinger Width / SMA20 | 18.7% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $21B |
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -3.8% | -0.19 | -0.59 | 62.1% | — |
| 42d | -5.6% | -0.11 | -0.59 | 62.1% | — |
| 63d | -6.4% | -0.13 | -0.59 | 62.1% | — |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 21.5× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 15.0× · 5 peers |
| Peer P/B | $22.19 | 16% | median 6.4× · 8 peers |
| Peer P/S | $23.13 | 16% | median 5.2× · 7 peers |
| Market Anchor (SMA50) | $115.19 | 68% | stability 84% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $22.6B
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, prote…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +4.52% | 23 |
| Feb | +6.65% | 23 |
| Mar | -4.61% | 23 |
| Apr | +4.95% | 23 |
| May | +1.26% | 23 |
| Jun | +2.09% | 23 |
| Jul | +2.45% | 22 |
| Aug | -3.93% | 22 |
| Sep | +10.25% | 23 |
| Oct | -0.91% | 23 |
| Nov | +8.73% | 23 |
| Dec | -1.22% | 23 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-08 | Pre-Market | 8.38% | 1.16% | 0.14x | Within |
| 2024-10-31 | Pre-Market | 9.32% | 4.26% | 0.46x | Within |
| 2025-05-08 | Pre-Market | 9.78% | 3.19% | 0.33x | Within |
| 2025-08-07 | Pre-Market | 10.83% | 1.19% | 0.11x | Within |
| 2025-10-30 | Pre-Market | 10.99% | 16.81% | 1.53x | Exceeded |
| 2026-02-19 | Pre-Market | 7.65% | 4.38% | 0.57x | Within |
| 2026-05-07 | Pre-Market | 12.40% | 23.41% | 1.89x | Exceeded |
- IV Rank (30D)
- 58.91
- IV Rank (7D)
- 58.91
- Avg IV
- 93.8%
- Straddle (30D)
- $11.25
- Straddle (7D)
- $11.25
- P/C Volume
- 0.36
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.57
- Correlation (SPY)
- 13.7%
- R²
- 0.02
- Ann. Volatility
- 52.2%
- SPY Volatility
- 12.5%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $80.99M | 22.54% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $62.09M | 17.28% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $54.70M | 15.22% | 2026-03-31 |
| 4 | CITIGROUP INC Custodian | $32.70M | 9.10% | 2026-03-31 |
| 5 | Squarepoint Ops LLC | $22.61M | 6.29% | 2026-03-31 |
| 6 | MILLENNIUM MANAGEMENT LLC Custodian | $22.45M | 6.25% | 2026-03-31 |
| 7 | JPMORGAN CHASE & CO Custodian | $16.10M | 4.48% | 2026-03-31 |
| 8 | Eversept Partners, LP | $15.37M | 4.28% | 2026-03-31 |
| 9 | Caption Management, LLC | $7.06M | 1.97% | 2026-03-31 |
| 10 | WOLVERINE TRADING, LLC Custodian | $6.32M | 1.76% | 2025-09-30 |
| 11 | NOMURA HOLDINGS INC | $4.91M | 1.37% | 2026-03-31 |
| 12 | CAPITAL FUND MANAGEMENT S.A. | $4.50M | 1.25% | 2026-03-31 |
| 13 | TUDOR INVESTMENT CORP ET AL | $4.02M | 1.12% | 2026-03-31 |
| 14 | Walleye Capital LLC | $3.78M | 1.05% | 2026-03-31 |
| 15 | IMC-Chicago, LLC Custodian | $3.73M | 1.04% | 2026-03-31 |
| 16 | SIMPLEX TRADING, LLC Custodian | $3.06M | 0.85% | 2026-03-31 |
| 17 | GROUP ONE TRADING LLC Custodian | $2.80M | 0.78% | 2026-03-31 |
| 18 | Walleye Trading LLC | $2.32M | 0.65% | 2026-03-31 |
| 19 | Point72 Asset Management, L.P. | $2.21M | 0.61% | 2026-03-31 |
| 20 | Tidal Investments LLC | $2.06M | 0.57% | 2026-03-31 |
| 21 | D. E. Shaw & Co., Inc. Custodian | $1.86M | 0.52% | 2026-03-31 |
| 22 | BALYASNY ASSET MANAGEMENT L.P. | $1.78M | 0.50% | 2026-03-31 |
| 23 | Alphadyne Asset Management LP | $1.05M | 0.29% | 2026-03-31 |
| 24 | HAP TRADING, LLC | $618.32K | 0.17% | 2025-09-30 |
| 25 | Cubist Systematic Strategies, LLC | $230.42K | 0.06% | 2025-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $67.04M | 28.04% | 2026-03-31 |
| 2 | Artia Global Partners LP | $45.74M | 19.13% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $17.94M | 7.50% | 2026-03-31 |
| 4 | Caption Management, LLC | $16.40M | 6.86% | 2026-03-31 |
| 5 | Jefferies Financial Group Inc. | $16.34M | 6.83% | 2026-03-31 |
| 6 | Parallax Volatility Advisers, L.P. | $14.42M | 6.03% | 2026-03-31 |
| 7 | 683 Capital Management, LLC | $9.81M | 4.10% | 2026-03-31 |
| 8 | CITADEL ADVISORS LLC Custodian | $8.31M | 3.47% | 2026-03-31 |
| 9 | NOMURA HOLDINGS INC | $8.18M | 3.42% | 2026-03-31 |
| 10 | WOLVERINE TRADING, LLC Custodian | $6.97M | 2.91% | 2025-09-30 |
| 11 | Walleye Capital LLC | $4.38M | 1.83% | 2026-03-31 |
| 12 | Point72 Asset Management, L.P. | $4.10M | 1.72% | 2026-03-31 |
| 13 | Centiva Capital, LP | $4.09M | 1.71% | 2026-03-31 |
| 14 | IMC-Chicago, LLC Custodian | $3.70M | 1.55% | 2026-03-31 |
| 15 | CAPITAL FUND MANAGEMENT S.A. | $3.34M | 1.40% | 2026-03-31 |
| 16 | PEAK6 LLC | $2.31M | 0.96% | 2026-03-31 |
| 17 | Squarepoint Ops LLC | $1.41M | 0.59% | 2026-03-31 |
| 18 | TUDOR INVESTMENT CORP ET AL | $1.19M | 0.50% | 2026-03-31 |
| 19 | D. E. Shaw & Co., Inc. Custodian | $899.36K | 0.38% | 2026-03-31 |
| 20 | Alphadyne Asset Management LP | $719.49K | 0.30% | 2026-03-31 |
| 21 | SIMPLEX TRADING, LLC Custodian | $605.02K | 0.25% | 2026-03-31 |
| 22 | Walleye Trading LLC | $572.32K | 0.24% | 2026-03-31 |
| 23 | GROUP ONE TRADING LLC Custodian | $441.50K | 0.18% | 2026-03-31 |
| 24 | Cubist Systematic Strategies, LLC | $216.01K | 0.09% | 2025-09-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-24 | Michael Alexander Smith | Chief Legal Officer | Sell (S) | −1,806 | $95.82 | -$173.1K | EDGAR |
| 2026-06-24 | Samuele Butera | SVP, GM, Global Respiratory | Award (A) | +7,342 | — | EDGAR | |
| 2026-06-10 | William Lewis | Chair and CEO | Sell (S) | −6,515 | $94.03 | -$612.6K | EDGAR |
| 2026-06-05 | Martina M.D. Flammer | Chief Medical Officer | Sell (S) | −4,424 | $102.90 | -$455.2K | EDGAR |
| 2026-06-05 | William Lewis | Chair and CEO | Sell (S) | −7,605 | $102.27 | -$777.8K | EDGAR |
| 2026-06-05 | Michael Alexander Smith | Chief Legal Officer | Sell (S) | −2,159 | $102.27 | -$220.8K | EDGAR |
| 2026-06-05 | Sara Bonstein | Chief Financial Officer | Sell (S) | −2,404 | $102.27 | -$245.9K | EDGAR |
| 2026-06-05 | Roger Adsett | Chief Operating Officer | Sell (S) | −2,370 | $102.27 | -$242.4K | EDGAR |
| 2026-05-22 | Michael Alexander Smith | Chief Legal Officer | Sell (S) | −6,149 | $108.47 | -$667.0K | EDGAR |
| 2026-05-20 | William Lewis | Chair and CEO | Mixed | −14,865 | $82.32 | -$2.45M | EDGAR |
| 2026-05-15 | William Lewis | Chair and CEO | Sell (S) | −13,283 | $116.18 | -$1.54M | EDGAR |
| 2026-05-15 | LEO LEE | Director | Award (A) | +3,305 | — | EDGAR | |
| 2026-05-15 | Clarissa Desjardins | Director | Award (A) | +3,305 | — | EDGAR | |
| 2026-05-15 | David R Brennan | Director | Award (A) | +3,305 | — | EDGAR | |
| 2026-05-15 | MELVIN MD SHAROKY | Director | Award (A) | +3,305 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | GEOFFREY ALLAN | President, CEO and Chairman | 1,826,682 | $188.84M | $118.0K | 3 | 2009-04-02 |
| 2 | KEVIN P TULLY | Executive VP & CFO | 597,290 | $61.75M | $34.2K | 5 | 2011-12-23 |
| 3 | William Lewis | Chair and CEO | 492,841 | $50.95M | -$115.62M | 91 | 2026-06-10 |
| 4 | Stephen C. Glover | President Follow-on Biologics | 477,162 | $49.33M | $62.9K | 3 | 2009-04-02 |
| 5 | STEINAR J ENGELSEN | Director | 320,802 | $33.16M | $834.3K | 24 | 2021-11-03 |
| 6 | Doug Farrar | Vice President, ITP | 292,055 | $30.19M | $0 | 2 | 2009-04-02 |
| 7 | MELVIN MD SHAROKY | Director | 252,928 | $26.15M | -$7.64M | 52 | 2026-05-15 |
| 8 | GRAHAM K CROOKE | Director | 228,404 | $23.61M | $8.4K | 6 | 2010-06-11 |
| 9 | KENNETH G CONDON | Director | 168,504 | $17.42M | $0 | 5 | 2010-06-11 |
| 10 | Dennis M Lanfear | Director | 168,404 | $17.41M | $0 | 5 | 2010-06-11 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-25 | William Lewis | Officer | 21,398 | $2.21M | 2026-06-25 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-22 | Michael Smith | Officer | 1,806 | $173.0K | 2026-06-22 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-08 | William Lewis | Officer | 6,515 | $612.6K | 2026-06-08 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-05 | Martina Flammer | Officer | 1,858 | $192.8K | 2026-06-05 | Merrill Lynch | 10b5-1 | EDGAR |
| 2026-06-03 | Sara Bonstein | Officer | 2,404 | $245.9K | 2026-06-03 | Merrill Lynch | — | EDGAR |
| 2026-06-03 | Martina Flammer | Officer | 2,566 | $262.4K | 2026-06-03 | Merrill Lynch | — | EDGAR |
| 2026-06-03 | Roger Adsett | Officer | 2,370 | $242.4K | 2026-06-03 | Merrill Lynch | — | EDGAR |
| 2026-06-03 | Michael Smith | Officer | 2,159 | $220.8K | 2026-06-03 | Merrill Lynch | — | EDGAR |
| 2026-06-03 | William Lewis | Officer | 7,605 | $777.8K | 2026-06-03 | Merrill Lynch | — | EDGAR |
| 2026-05-22 | Michael Smith | Officer | 6,149 | $667.0K | 2026-05-22 | Merrill Lynch | 10b5-1 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-15 | 0001140361-26-021648 | EDGAR |
| 2026-05-07 | 0001140361-26-019430 | EDGAR |
| 2026-04-07 | 0001140361-26-013659 | EDGAR |
| 2026-03-23 | 0001140361-26-010651 | EDGAR |
| 2026-02-19 | 0001140361-26-006116 | EDGAR |
| 2026-01-09 | 0001140361-26-000778 | EDGAR |
| 2025-12-17 | 0001140361-25-045836 | EDGAR |
| 2025-11-18 | 0001140361-25-042598 | EDGAR |
| 2025-10-30 | 0001140361-25-039789 | EDGAR |
| 2025-08-12 | 0001140361-25-030537 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-19 | 0001104506-26-000009 | EDGAR |
| 2025-02-20 | 0001104506-25-000009 | EDGAR |
| 2024-02-22 | 0001104506-24-000008 | EDGAR |
| 2023-02-23 | 0001104506-23-000009 | EDGAR |
| 2022-02-17 | 0001104506-22-000008 | EDGAR |
| 2021-02-25 | 0001104506-21-000005 | EDGAR |
| 2020-02-25 | 0001104506-20-000007 | EDGAR |
| 2019-02-22 | 0001104506-19-000009 | EDGAR |
| 2018-02-23 | 0001104506-18-000002 | EDGAR |
| 2017-02-23 | 0001047469-17-000856 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-07 | 0001104506-26-000032 | EDGAR |
| 2025-10-30 | 0001104506-25-000053 | EDGAR |
| 2025-08-07 | 0001104506-25-000043 | EDGAR |
| 2025-05-08 | 0001104506-25-000026 | EDGAR |
| 2024-10-31 | 0001104506-24-000033 | EDGAR |
| 2024-08-08 | 0001104506-24-000026 | EDGAR |
| 2024-05-09 | 0001104506-24-000016 | EDGAR |
| 2023-10-26 | 0001104506-23-000025 | EDGAR |
| 2023-08-03 | 0001104506-23-000018 | EDGAR |
| 2023-05-04 | 0001104506-23-000012 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 32.1 |
| P/S Ratio | 27.6 |
| EV/EBITDA | -19.9 |
| TTM Revenue | $0.8B |
| TTM Net Income | $-1.2B |
| TTM EPS | $-5.74 |
| ROE | -167.9% |
| Debt/Equity | 0.80 |